Observing treatment outcomes in DLBCL patients with different genetic subtypes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect and evaluate real-world data on treatment regimens, efficacy, safety, and survival outcomes for patients diagnosed with diffuse large B-cell lymphoma (DLBCL) across various genetic subtypes. By analyzing clinical characteristics and prognostic factors, the study seeks to enhance understanding of how different molecular subtypes of DLBCL respond to treatment. Data will be gathered from actual clinical practice cases, including patient demographics, tumor characteristics, treatment history, and adverse reactions. The findings are expected to inform future precision therapies for DLBCL.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
* Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
* Fully comprehension and signature of the informed consent form (ICF) for participation

Exclusion Criteria:

* Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
* Severe mental illness
* Patients deemed unsuitable for inclusion by the investigator

Where it's running

• Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Weili Zhao
• Email: zwl_trial@163.com
• Phone: +862164370045

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MDX2003 for adults with relapsed B‑cell lymphomas

  This trial will test MDX2003 in adults with relapsed or refractory B‑cell lymphomas whose tumors are CD19 or CD20 positive to see if it is safe and can shrink tumors.

  Recruiting at 7 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Richmond, Victoria and 6 other locations · NCT07249905

• Training for oncologists to improve communication with lymphoma patients

  This study tests a new training program for oncologists to help them communicate better with patients who have diffuse large B-cell lymphoma about their diagnosis and care options.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT05940272

• LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma

  This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.

  Recruiting Phase 1 Leukos Biotech S.L. · Barcelona, Barcelona · NCT07914348

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma

  This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07779018

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.